There are multiple chapters near you. Select your preferred chapter.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.

Staffing and certain compliance issues related to updated survey guidance coming in late March, particularly those that relate to patient discharges as ...

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Enzalutamide was approved after the publication of a phase III, [37] double-blind placebo-controlled randomized trial by Scher et el (AFFIRM TRIAL) in which 1199 men with mCRPC were randomized ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 (Ra-223) for androgen receptor pathway inhibitor (ARPI)–naive metastatic ...

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...

Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...

They were either given BAT or enzalutamide [Xtandi], which is [the] standard of care. [In] all…these patients, abiraterone [Zytiga] had failed, so then they were eligible for enzalutamide. The authors ...